We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Proline-Specific Peptidase Activities in Plasma of Hospitalized COVID-19 Patients

By LabMedica International staff writers
Posted on 16 Mar 2022

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can elicit a protracted pneumonitis, but also kidney, cardiovascular and neurological complications and thromboembolic phenomena of unclear pathogenesis.

These COVID-19 patients experience several features of dysregulated immune system observed in sepsis. The activity of proline-specific peptidases in plasma of COVID-19 hospitalized patients has been investigated. The peptidases studied were dipeptidyl peptidase 4 (DPP4), fibroblast activation protein alpha (FAP), prolyl oligopeptidase (PREP) and prolylcarboxpeptidase (PRCP).


Image: The HPLC model: LC-2050 series, three types of detector setup (UV, PDA, detector-less) are available to suit any analysis methods and aims (Photo courtesy of Shimadzu)
Image: The HPLC model: LC-2050 series, three types of detector setup (UV, PDA, detector-less) are available to suit any analysis methods and aims (Photo courtesy of Shimadzu)

Medical Biochemists at the University of Antwerp (Antwerp, Belgium) and their colleagues collected heparin plasma samples from 56 hospitalized patients with laboratory-confirmed (PCR test) COVID-19 shortly after hospital admission (=baseline, 1 to 5 days after hospital admission) and thereafter at irregular time points until discharge. Additionally, plasma was taken from a control group of 32 healthy volunteers.

The scientists measured DPP4 activity colorimetrically using the substrate Gly-Pro-pNA. FAP and PREP activity was measured fluorometrically using Z-Gly-Pro-AMC in a combined FAP/PREP assay. PRCP activity was determined by measuring the hydrolysis of Z-Pro-Phe by use of a reversed-phase high-performance liquid chromatography technique. The enzymatically formed Z-Pro was tracked by its UV absorbance at 210 nm after separation on a Shimadzu HPLC apparatus (Kyoto, Japan).

The investigators reported that compared to healthy controls, both DPP4 and FAP activities were significantly lower in COVID-19 patients at hospital admission and FAP activity further decreased significantly in the first week of hospitalization. While PRCP activity remained unchanged, PREP activity was significantly increased in COVID-19 patients at hospitalization and further increased during hospital stay and stayed elevated until the day of discharge.

The authors concluded that a similar pattern in the proline-specific peptidase activities in COVID-19 patients compared with patients experiencing septic shock: decreased DPP4 and FAP activity and elevated PREP activity. The study was published on March 10, 2022 in the journal Clinica Chimica Acta.

Related Links:
University of Antwerp 
Shimadzu 


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Luteinizing Hormone Test
Luteinizing Hormone (LH) Rapid Test
New
Giardia Assay
AccuDiag Giardia

Latest Clinical Chem. News

Portable Diagnostic Tool Uses Bioluminescence to Detect Viruses at POC

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

AI-Powered Blood Test Accurately Detects Ovarian Cancer